id,source,text,arguments
0,EGRAM,"Adult naive T cells, which are at rest in normal conditions, are observed to proliferate strongly when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
1,EGRAM,"Adult naive T cells, which are at rest in normal conditions, can proliferate strongly when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
2,EGRAM,"Adult naive T cells, which are at rest in normal conditions, have proliferated when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
3,EGRAM,"Adult naive T cells, which are at rest in normal conditions, may proliferate strongly when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
4,EGRAM,"Adult naive T cells, which are at rest in normal conditions, proliferated strongly when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
5,EGRAM,"After androgen withdrawal and antiandrogen treatment, the androgen responsive prostate cancer cells that ceased to proliferate and underwent apoptosis caused tumor regression.",{'0': 'the androgen responsive prostate cancer cells'}
6,EGRAM,Cancer cells can be characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'Cancer cells'}
7,EGRAM,Cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'Cancer cells'}
8,EGRAM,Cancer cells was characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'Cancer cells'}
9,EGRAM,"HSC can continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
10,EGRAM,"HSC is able to continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
11,EGRAM,"HSC is observed to continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
12,EGRAM,"HSC will continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
13,EGRAM,"HSC will continue to proliferate in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
14,EGRAM,"HSC will continue to proliferate strongly in the bone marrow and spleen through 8 days of G-CSF treatment, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
15,EGRAM,"Intrasplenically transplanted fetal liver cells, as our results have shown, have the ability to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.",{'0': 'intrasplenically transplanted fetal liver cells'}
16,EGRAM,"Intrasplenically transplanted fetal liver cells, as our results have shown, proliferated and differentiated into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.",{'0': 'intrasplenically transplanted fetal liver cells'}
17,EGRAM,"Our observations illustrate that the human placenta can be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
18,EGRAM,"Our observations illustrate that the human placenta is able to be endowed with the biochemical machinery to proliferate indefinitely throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
19,EGRAM,"Our observations illustrate that the human placenta is shown to be endowed with the biochemical machinery to proliferate throughout gestation, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
20,EGRAM,Stat5ab-/-peripheral T cells can regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).,"{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
21,EGRAM,Stat5ab-/-peripheral T cells will regain the ability to proliferate indefinitely upon introduction of full-length wild-type Stat5a (Figure 6B).,"{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
22,EGRAM,The ability of EBD cells being observed to proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
23,EGRAM,The ability of EBD cells that can proliferate in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
24,EGRAM,The ability of EBD cells that is able to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
25,EGRAM,The ability of EBD cells that is observed to proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
26,EGRAM,The ability of EBD cells that may have proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
27,EGRAM,The ability of EBD cells that may have strongly proliferated in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
28,EGRAM,The ability of EBD cells that will proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
29,EGRAM,The ability of EBD cells that will proliferate strongly in vivo was examined by injection of 3 ? 106 LVEC cells into the calf muscle of 3 immunocompromised mice.,{'0': 'EBD cells'}
30,EGRAM,These results show that intrasplenically transplanted fetal liver cells are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.,{'0': 'intrasplenically transplanted fetal liver cells'}
31,EGRAM,These results show that intrasplenically transplanted fetal liver cells are able to proliferate and differentiate into mature cells displaying a GST expression pattern with respective enzyme activities similar to adult liver.,{'0': 'intrasplenically transplanted fetal liver cells'}
32,EGRAM,"Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has the ability to significantly impair their capacity to proliferate when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
33,EGRAM,"Treatment of endothelial cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
34,EMBO,Stat5ab-/-peripheral T cells regain the ability to proliferate upon introduction of full-length wild-type Stat5a (Figure 6B).,"{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
35,PERMUTATE,Adult naive T cells can regain the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).,"{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
36,PERMUTATE,Adult naive T cells can regain the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).,"{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
37,PERMUTATE,Adult naive T cells have the probability of regaining the ability to proliferate indefinitely when transferred to lymphopenic hosts (Figure 6B).,"{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
38,PERMUTATE,Adult naive T cells have the probability of regaining the ability to proliferate when transferred to lymphopenic hosts (Figure 6B).,"{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
39,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells are observed to cease to proliferate and undergo apoptosis, causing tumor regression.",{'0': 'Cancer cells'}
40,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells being observed to cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'Cancer cells'}
41,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells have the ability to cease to proliferate and undergo apoptosis, causing tumor regression.",{'0': 'Cancer cells'}
42,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells having ceased to proliferate and undergo apoptosis caused tumor regression.",{'0': 'Cancer cells'}
43,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'Cancer cells'}
44,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'Cancer cells'}
45,PERMUTATE,"After androgen withdrawal and antiandrogen treatment, Cancer cells that have ceased to proliferate and undergo apoptosis caused tumor regression.",{'0': 'Cancer cells'}
46,PERMUTATE,"Further, HSC are able to be proven to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
47,PERMUTATE,"Further, HSC could be observed to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
48,PERMUTATE,"Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
49,PERMUTATE,"Further, HSC have been found to proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
50,PERMUTATE,"Further, HSC have been proven to strongly proliferate in response to HIV antigens through 8 days of G-CSF treatment in the bone marrow and spleen.","{'0': 'HSC', '1': 'through 8 days of G-CSF treatment'}"
51,PERMUTATE,"HIV-specific CD4+ T cells of viremic patients has the ability to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HIV-specific CD4+ T cells of viremic patients', '1': 'when costimulation was provided by anti-CD28 antibody'}"
52,PERMUTATE,"HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HIV-specific CD4+ T cells of viremic patients', '1': 'when costimulation was provided by anti-CD28 antibody'}"
53,PERMUTATE,"HIV-specific CD4+ T cells of viremic patients is observed to continue to proliferate strongly in vitro when costimulation was provided by anti-CD28 antibody, but HSC released into the blood tended to be in G0/G1 phase.","{'0': 'HIV-specific CD4+ T cells of viremic patients', '1': 'when costimulation was provided by anti-CD28 antibody'}"
54,PERMUTATE,"Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
55,PERMUTATE,"Our observations illustrate that Stat5ab-/-peripheral T cells is able to be endowed with the biochemical machinery to proliferate upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
56,PERMUTATE,"Our observations illustrate that Stat5ab-/-peripheral T cells will be endowed with the biochemical machinery to proliferate indefinitely upon introduction of full-length wild-type Stat5a, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
57,PERMUTATE,"Our observations illustrate that endothelial cells can be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
58,PERMUTATE,"Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
59,PERMUTATE,"Our observations illustrate that endothelial cells has the ability to be endowed with the biochemical machinery to proliferate indefinitely when exposed to FGF2, yet, there are intrinsic mechanisms that effectively circumscribe the extent and duration of trophoblast proliferation.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
60,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, are observed to proliferate strongly upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
61,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have proliferated strongly upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
62,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, could have strongly proliferated upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
63,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, may proliferate upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
64,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will proliferate strongly upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
65,PERMUTATE,"Stat5ab-/-peripheral T cells, which are at rest in normal conditions, will strongly proliferate upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
66,PERMUTATE,"Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has impaired their capacity to proliferate when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
67,PERMUTATE,"Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, has significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
68,PERMUTATE,"Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to impair their capacity to proliferate when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
69,PERMUTATE,"Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, significantly impaired their capacity to proliferate when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
70,PERMUTATE,"Treatment of Adult naive T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate when transferred to lymphopenic hosts.","{'0': 'Adult naive T cells', '1': 'when transferred to lymphopenic hosts'}"
71,PERMUTATE,"Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
72,PERMUTATE,"Treatment of Stat5ab-/-peripheral T cells of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, will significantly impair their capacity to proliferate upon introduction of full-length wild-type Stat5a.","{'0': 'Stat5ab-/-peripheral T cells', '1': 'upon introduction of full-length wild-type Stat5a'}"
73,PERMUTATE,"Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, can significantly impair their capacity to proliferate throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
74,PERMUTATE,"Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, impairs their capacity to proliferate throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
75,PERMUTATE,"Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is able to significantly impair their capacity to proliferate throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
76,PERMUTATE,"Treatment of the human placenta of different origin with the ganglioside biosynthesis inhibitors fumonisin B1, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or D-1-threo-1-phenyl-2-hexa-decanoylamino-3-pyrrolidino-1-propanol-HCl, is observed to significantly impair their capacity to proliferate throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
77,PERMUTATE,endothelial cells have regained the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).,"{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
78,PERMUTATE,endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).,"{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
79,PERMUTATE,endothelial cells have the probability of regaining the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).,"{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
80,PERMUTATE,endothelial cells will regain the ability to proliferate indefinitely when exposed to FGF2 (Figure 6B).,"{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
81,PERMUTATE,"endothelial cells, which are at rest in normal conditions, can strongly proliferate when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
82,PERMUTATE,"endothelial cells, which are at rest in normal conditions, have the ability to proliferate when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
83,PERMUTATE,"endothelial cells, which are at rest in normal conditions, might have proliferated strongly when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
84,PERMUTATE,"endothelial cells, which are at rest in normal conditions, might have strongly proliferated when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
85,PERMUTATE,"endothelial cells, which are at rest in normal conditions, proliferated when exposed to FGF2.","{'0': 'endothelial cells', '1': 'when exposed to FGF2'}"
86,PERMUTATE,the androgen responsive prostate cancer cells are believed to be characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'the androgen responsive prostate cancer cells'}
87,PERMUTATE,the androgen responsive prostate cancer cells are characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'the androgen responsive prostate cancer cells'}
88,PERMUTATE,the androgen responsive prostate cancer cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'the androgen responsive prostate cancer cells'}
89,PERMUTATE,the human placenta are able to regain the ability to proliferate throughout gestation (Figure 6B).,"{'0': 'the human placenta', '1': 'throughout gestation'}"
90,PERMUTATE,the human placenta may have regained the ability to proliferate throughout gestation (Figure 6B).,"{'0': 'the human placenta', '1': 'throughout gestation'}"
91,PERMUTATE,the human placenta will regain the ability to proliferate throughout gestation (Figure 6B).,"{'0': 'the human placenta', '1': 'throughout gestation'}"
92,PERMUTATE,"the human placenta, which are at rest in normal conditions, are observed to proliferate strongly throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
93,PERMUTATE,"the human placenta, which are at rest in normal conditions, could have proliferated strongly throughout gestation.","{'0': 'the human placenta', '1': 'throughout gestation'}"
94,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells ceasing to proliferate and underwent apoptosis caused tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
95,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells having ceased to proliferate and undergo apoptosis caused tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
96,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells may cease to proliferate and undergo apoptosis, causing tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
97,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
98,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that are able to cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
99,REPLACE,"After androgen withdrawal and antiandrogen treatment, intrasplenically transplanted fetal liver cells that will cease to proliferate and undergo apoptosis will cause tumor regression.",{'0': 'intrasplenically transplanted fetal liver cells'}
100,REPLACE,intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'intrasplenically transplanted fetal liver cells'}
101,REPLACE,intrasplenically transplanted fetal liver cells has been characterized by either an increased ability to strongly proliferate or a diminished capacity to undergo programmed cell death.,{'0': 'intrasplenically transplanted fetal liver cells'}
